← Eichor
Study identifier: NCT06615752 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)  ·  Sponsor: Charles Drew University of Medicine and Science

PhasePhase 1/Phase 2
Planned participants99
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.

This description comes directly from the study's public registry record.

Talk to the study team

Piwen Wang, PhD  ·  3235634999  ·  PiwenWang@cdrewu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Charles R. Drew University of Medicine and ScienceLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06615752